AUTL
Autolus Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
AUTL Profile
Autolus Therapeutics Plc
A clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies
Biological Technology
02/02/2018
06/22/2018
NASDAQ Stock Exchange
647
12-31
Depository Receipts (Ordinary Shares)
The MediaWorks, 191 Wood Lane, London W12 7FP , United Kingdom
--
Autolus Therapeutics plc was incorporated in England and Wales on February 2, 2018. The company is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer and autoimmune diseases. Using the company's extensive suite of proprietary and modular T-cell programming technologies, the company is designing precisely targeted, controlled and highly active T-cell therapies designed to better identify target cells, break down their defense mechanisms, and attack and eliminate these cells.